Market Overview

Morgan Stanley Downgrades Teva, Endo On Drug Pricing And Litigation Concerns

Share:
Morgan Stanley Downgrades Teva, Endo On Drug Pricing And Litigation Concerns

Pharmaceutical stocks have been under pressure for the past few trading days, but one Wall Street analyst said the worst is yet to come for a handful of specialty drugmakers.

The Analyst

Morgan Stanley analyst David Risinger made the following changes to his pharma stock coverage:

  • Endo International PLC (NASDAQ: ENDP) downgraded from Equal-Weight to Underweight, price target lowered from $8 to $3.
  • Teva Pharmaceutical Industries Ltd (NYSE: TEVA) downgraded from Equal-Weight to Underweight, price target lowered from $16 to $6.
  • Mylan NV (NASDAQ: MYL) reiterated at Overweight, price target lowered from $32 to $22.
  • Amneal Pharmaceuticals Inc (NYSE: AMRX) reiterated at Equal-Weight, price target lowered from $12 to $4.

The Thesis

Risinger said pharma investors can expect significant earnings multiple contraction due to extended buying group pricing pressures coupled with increasing competition among generic drug manufacturers. In addition, he said Endo and Teva are facing legal uncertainty as well.

“Although stocks have underperformed, we are most concerned about further potential downside for ENDP & TEVA due to branded opioid exposure,” Risinger wrote in a note.

There are thousands of opioid-related lawsuits that are just getting started, and Teva has already announced one opioid settlement with the state of Oklahoma. In addition to legal concerns about opioids, at least 44 U.S. states have joined a lawsuit alleging generic drug price fixing as well.

Risinger said these legal risks coupled with high debt leverage will likely discourage companies from extending their balance sheets on acquisitions, particularly Endo and Teva.

Price Action

Here’s how the stocks mentioned were trading on Monday morning:

  • Teva was down 8.7%.
  • Amneal was down 6.2%.
  • Mylan was down 1%.
  • Endo was down 2.8%.

Related Links:

Washington Worries Trigger Bearish Merck Options Trades

Piper Jaffray: Tilray, GW Pharma Are Early Leaders In Medical Cannabis

Latest Ratings for ENDP

DateFirmActionFromTo
Jul 2019DowngradesEqual-WeightUnderweight
Jul 2019DowngradesOutperformSector Perform
Jun 2019DowngradesBuyNeutral

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Analyst Color Short Ideas Downgrades Health Care Price Target Top Stories Analyst Ratings Trading Ideas Best of Benzinga

 

Related Articles (ENDP + AMRX)

View Comments and Join the Discussion!

Port Report: Shipping Lines, Ports Pledge Support To Blockchain Group

XRP/USD Lock-Step Trading Stalls Under $0.32